Table 2.
Clinical and Inflammatory Characteristics of Patients with Severe Asthma Treated with or without Long-Acting Anti-Muscarinic Agents (LAMA)
| LAMA Non Users | LAMA Users | p values | |
|---|---|---|---|
| Annual exacerbation rate | 2.4 ± 3.2 | 3.9 ± 7.6 | <0.01 |
| ACT | 18.4 ± 5.2 | 17.2 ± 5.2 | 0.01 |
| ACQ | 2.5 ± 1.5 | 2.9 ± 1.5 | 0.01 |
| AQLQ | 4.7 ± 1.4 | 4.2 ± 1.3 | <0.01 |
| Exhaled nitric oxide (FENO), ppb | 47.8 ± 50.1 | 40.7 ± 35.4 | 0.20 |
| Concomitant bronchiectasis (%) | 13.1 | 25.5 | <0.01 |
| Concomitant GERD (%) | 54.0 | 58.4 | 0.15 |
| Concomitant Rhinitis (%) | 61.1 | 55.9 | 0.14 |
| Concomitant CRSwNP (%) | 38.4 | 45.9 | 0.08 |
| Concomitant Atopic Dermatitis (%) | 4.8 | 5.6 | 0.39 |
| Blood eosinophils (cells/mcl) | 453.9 ± 559.7 | 562.9 ± 668.3 | 0.03 |
| Serum total IgE (UI/mL) | 494.1 ± 876.8 | 417.2 ± 823.6 | 0.35 |
| Inhaled corticosteroids (ICS) mean dose (mcg, Fluticasone equivalents) | 1111.4 ± 644.8 | 1079.7 ± 541.4 | 0.54 |
| Long term oral corticosteroids (OCS) use (%) | 36.9 | 62.9 | <0.01 |
| OCS mean dose (mg, Prednisone equivalents) | 16.3 ± 18.7 | 13.4 ± 9.3 | 0.18 |
Concomitant biologic treatments (%)
|
54.1 35.1 29.0 |
66.5 30.7 35.8 |
0.01 0.16 <0.01 |
Notes: Statistically significant p values are reported in bold font. Data about ACT were available in 351 patients, ACQ in 390, AQLQ in 423, FENO in 269, blood eosinophils in 459, serum total IgE in 438.